| 6.63 0.45 (7.28%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.32 |
1-year : | 9.72 |
| Resists | First : | 7.13 |
Second : | 8.32 |
| Pivot price | 6.53  |
|||
| Supports | First : | 6.33 |
Second : | 5.84 |
| MAs | MA(5) : | 6.42 |
MA(20) : | 6.55 |
| MA(100) : | 5.69 |
MA(250) : | 4.32 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.6 |
D(3) : | 26.9 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 7.13 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STLN ] has closed below upper band by 40.0%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.85 - 6.89 | 6.89 - 6.92 |
| Low: | 6.09 - 6.13 | 6.13 - 6.18 |
| Close: | 6.56 - 6.63 | 6.63 - 6.7 |
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Thu, 01 Oct 2026
Cancer doctors will discuss clinical trial access and mental health care - Stock Titan
Thu, 01 Oct 2026
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation - Yahoo Finance
Wed, 30 Sep 2026
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating (NASDAQ:STLN) - Seeking Alpha
Mon, 24 Aug 2026
Starling Oncology (STLN) director sells 298K shares under 10b5-1 plan - Stock Titan
Wed, 19 Aug 2026
Starling Oncology Builds Own Utilization Management Platform - HCI Innovation Group
Mon, 10 Aug 2026
US$9.00 - That's What Analysts Think Starling Oncology, Inc. (NASDAQ:STLN) Is Worth After These Results - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 102 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 17.7 (%) |
| Held by Institutions | 46.8 (%) |
| Shares Short | 6,790 (K) |
| Shares Short P.Month | 6,820 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | -6.2 % |
| Operating Margin | -2.9 % |
| Return on Assets (ttm) | -9.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 34.5 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 5.76 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -22.87 |
| PEG Ratio | 0 |
| Price to Book value | -26.53 |
| Price to Sales | 1.15 |
| Price to Cash Flow | 2060.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|